Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation
Director departure

INTERPACE BIOSCIENCES, INC. (IDXG) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 8-K Quarterly results
05/12/2023 8-K Quarterly results
Docs: "Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results"
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/27/2023 8-K Quarterly results
03/27/2023 10-K Annual Report for the period ended December 31, 2022
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/15/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
11/04/2022 8-K Quarterly results
10/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SEVERANCE AND CONSULTING AGREEMENT AND GENERAL RELEASE"
09/20/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/20/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/09/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
09/07/2022 8-K Acquisition/merger/asset purchase announced
Docs: "Execution Version",
"Execution Version",
"Unaudited Pro Forma Condensed Consolidated Financial Information The unaudited pro forma condensed consolidated financial statements were prepared to assist readers in understanding the nature and effects of the sale by Interpace Biosciences, Inc., , on August 31, 2022 of substantially all of the assets and the ongoing business comprising the Company’ s Pharma Services business pursuant to the Asset Purchase Agreement, dated as of August 31, 2022, by and among Flagship Biosciences, Inc. , Interpace Pharma Solutions, Inc. and the Company . The unaudited pro forma condensed consolidated statements of operations for the six months ended June 30, 2022, and for the year ended December 31, 2021 have been prepared with the assumption that the Asset Sale was completed as of January 1, 2021. The Un..."
08/15/2022 8-K Quarterly results
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/16/2022 RW Form RW - Registration Withdrawal Request:
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/16/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/29/2022 10-K/A Annual Report for the period ended December 31, 2021 [amend]
04/14/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
03/31/2022 8-K Quarterly results
Docs: "INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2021 2020 2021 2020 Revenue, net $ 10,853 $ 9,646 $ 41,314 $ 32,398 Cost of revenue 6,404 6,517 23,369 21,673 Gross Profit 4,449 3,129 17,945 10,725 Sales and marketing 2,482 2,478 10,067 9,254 Research and development 407 673 1,882 2,795 General and administrative 4,030 5,508 13,669 18,192 Transition expenses 111 1,780 2,585 2,578 Loss on DiamiR transaction 248 - 13 - Acquisition amortization expense 728 1,115 4,064 4,461 Change in fair value of contingent consideration Total operating expenses 7,725 11,065 31,942 36,791 Operating loss Interest accretion expense Related party interest - - Other income, net 467 Loss from continuing operations before ta..."
02/10/2022 SC 13G Singer Douglas Mark reports a 7% stake in Interpace Biosciences, Inc.
02/01/2022 SC 13D/A Kamin Peter reports a 18.6% stake in Interpace Biosciences, Inc.
01/28/2022 8-K Quarterly results
01/27/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
01/13/2022 SC 13D/A Kamin Peter reports a 18.6% stake in Interpace Biosciences, Inc.
01/13/2022 EFFECT Form EFFECT - Notice of Effectiveness:
01/07/2022 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
01/03/2022 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy